Drug Trial Radar · NCT07828210
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Sep 10, 2026
Primary completion
Sep 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- EVD Pharmacy and Medical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard treatment or standard treatment alone for 12 weeks.
Conditions
- Stroke
- Stroke, Acute Ischemic
- Stroke, Ischemic
- Stroke, Cryptogenic
- Stroke, Cardiovascular
Interventions
MLC901Drug
MLC901 (NeuroAiD™ II) 400 mg hard capsules, administered orally at a dose of 2 capsules three times daily for 12 weeks, in combination with standard treatment according to the protocol.
Standard treatment for acute ischemic strokeOther
Participants will receive standard treatment for acute ischemic stroke according to the study protocol for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- EuroQol 5-Dimension 5-Level (EQ-5D-5L)Time frame: Baseline, Day 7 and Day 14
- EuroQol Visual Analogue Scale (EQ-VAS)Time frame: Baseline, Day 7 and Day 14
- Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM-1.4)Time frame: Baseline, Day 7 and Day 14
- Adverse EventsTime frame: From baseline through Week 12, and at the optional Week 24 follow-up visit.
- Hemorrhagic ComplicationsTime frame: From baseline through Week 12, and at the optional Week 24 follow-up visit.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Traditional Medicine Institute
Ho Chi Minh City, Vietnam · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.